| The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes Y Cai, EJ Geutjes, K De Lint, P Roepman, L Bruurs, LR Yu, W Wang, ... Oncogene 33 (17), 2157-2168, 2014 | 135 | 2014 |
| ELOF1 is a transcription-coupled DNA repair factor that directs RNA polymerase II ubiquitylation Y Van der Weegen, K de Lint, D van den Heuvel, Y Nakazawa, ... Nature cell biology 23 (6), 595-607, 2021 | 46 | 2021 |
| Sensitizing triple-negative breast cancer to PI3K inhibition by cotargeting IGF1R K de Lint, JB Poell, H Soueidan, K Jastrzebski, J Vidal Rodriguez, ... Molecular cancer therapeutics 15 (7), 1545-1556, 2016 | 39 | 2016 |
| TNFa and IL2 encoding oncolytic adenovirus activates pathogen and danger-associated immunological signaling C Heiniö, R Havunen, J Santos, K de Lint, V Cervera-Carrascon, ... Cells 9 (4), 798, 2020 | 32 | 2020 |
| Integrative modeling identifies key determinants of inhibitor sensitivity in breast cancer cell lines K Jastrzebski, B Thijssen, RJC Kluin, K De Lint, IJ Majewski, ... Cancer research 78 (15), 4396-4410, 2018 | 22 | 2018 |
| BIRC2–BIRC3 amplification: a potentially druggable feature of a subset of head and neck cancers in patients with Fanconi anemia K Roohollahi, Y de Jong, G Pai, MA Zaini, K de Lint, D Sie, MA Rooimans, ... Scientific reports 12 (1), 45, 2022 | 10 | 2022 |
| MMS22L-TONSL functions in sister chromatid cohesion in a pathway parallel to DSCC1-RFC JJM van Schie, K de Lint, GM Pai, MA Rooimans, RMF Wolthuis, ... Life science alliance 6 (2), 2023 | 7 | 2023 |
| CRISPR screens in sister chromatid cohesion defective cells reveal PAXIP1-PAGR1 as regulator of chromatin association of cohesin JJM van Schie, K de Lint, TM Molenaar, M Moronta Gines, JA Balk, ... Nucleic Acids Research 51 (18), 9594-9609, 2023 | 3 | 2023 |
| Genome-wide CRISPR-Cas9 screen to identify new proteins involved in intracellular cholesterol transport A Meurs, K De Lint, N Zelcer Atherosclerosis 355, 9-10, 2022 | | 2022 |
| 91 4E-BP1 expression levels determine sensitivity of triple negative breast cancer cells to mTOR inhibitors K Jastrzebski, B Thijssen, JV Rodriguez, K de Lint, C Lieftink, LF Wessels, ... European Journal of Cancer, 34, 2014 | | 2014 |
| 673 Identification of Therapeutic Targets and Predictors of Response in Triple Negative Breast Cancer K Jastrzebski, J Vidal-Rodriguez, CJ Lieftink, TA Knijnenburg, KW de Lint, ... european journal of cancer, S159, 2012 | | 2012 |
| 554 Identification of Synthetic Lethal Interactions with Oncogenic Ras Through Large Scale Functional Genomic Screening RL Beijersbergen, J Vidal-Rodriguez, C Lieftink, K De Lint, J Poell, ... European Journal of Cancer, 170, 2012 | | 2012 |
Katarzyna (Kathy) JastrzebskiNKI-AvLVerified email at nki.nl
